Track SLGL and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$224.83M
Enterprise Value$201.77M
Revenue (TTM)$19.39M
Net Income (TTM)-$6.13M
Free Cash Flow (TTM)-$26.76M
Financial Health
Cash$24.00M
Net Debt-$23.06M
Debt Ratio0.03
Debt to Equity0.04
Interest Coverage-
Valuation (TTM)
Price to Sales11.6
Price to Earnings-36.69
EV to EBITDA18.52
Price to Book9.86
Price to Free Cash Flow-8.4
Margins (TTM)
Gross Profit Margin100.00%
EBITDA Margin56.18%
Operating Income Margin54.39%
Net Income Margin-31.60%
Free Cash Flow Margin-138.01%
Returns (5Y Avg)
Return on Invested Capital-33.88%
Return on Assets-29.91%
Return on Equity-32.71%
Return on Total Capital-33.88%
Return on Capital Employed-35.11%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue17.19%
Diluted EPS-6.34%
Total Debt-5.96%
Capital Expenditures-36.32%
Free Cash Flow1000.00%
CAGR (3Y)
Revenue70.92%
Diluted EPS-14.47%
Total Debt-11.66%
Capital Expenditures-34.98%
Free Cash Flow30.25%
CAGR (1Y)
Revenue68.04%
Diluted EPS159.86%
Total Debt15.12%
Capital Expenditures1000.00%
Free Cash Flow1000.00%
$89.74+$9.64|+10.74%
Last updated: Jul 21, 4:00 PM ET
52W High$97.97
52W Low$8.02
50D SMA$73.48
200D SMA$62.09
Volume57.74K
Sol Gel Technologies Ltd
7 Golda Meir Street, Ness Ziona, Israel, 7403650
IPO
2018
Employees
28
Industry
Biotechnology
Sector
Healthcare
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20260+3
3
Q4 20250+9
9
2-quarter cumulative
0 sells12 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0